HONG KONG – As it works to clear out a long-standing backlog while strengthening the country's regulatory environment, the CFDA processed twice as many applications last year.
HONG KONG – As it works to clear out a long-standing backlog while strengthening the country’s regulatory environment, the CFDA processed twice as many applications last year.
Three months after the Japanese conglomerate Toshiba Corp. decided to cut loose of its health care and services unit, industry giant Canon Inc. is likely to scoop it up for $6 billion.
HONG KONG – Three months after its first Chinese deal, South Korean clinical-stage biotech company Genexine Inc. (KOSDAQ:095700) is continuing its venture into China by out-licensing another drug candidate to one of the country's leading pharmaceutical companies.
HONG KONG – Taiwan's JHL Biotech Inc. has received approval to start clinical trials of a biosimilar to Roche AG's Rituxan (rituximab), marking the first European clinical trial approval for a monoclonal antibody biosimilar developed in the Greater China region.
HONG KONG — At Chinese State Council meetings in February, Premier Li Keqiang emphasized the importance of innovation and upgrades to the health care sector, once again highlighting the importance of the pharmaceutical and medical device industries for China's next phase of development. Even as China's economy and international trade slows down, the med-tech sector continues to surge forward.
HONG KONG – Three months after its first Chinese deal, South Korean clinical-stage biotech company Genexine Inc. (KOSDAQ:095700) is continuing its venture into China by out-licensing another drug candidate to one of the country's leading pharmaceutical companies.
HONG KONG – Taiwan's JHL Biotech Inc. has received approval to start clinical trials of a biosimilar to Roche AG's Rituxan (rituximab), marking the first European clinical trial approval for a monoclonal antibody biosimilar developed in the Greater China region.
